KPMG Speaks On What 2022 Medtech Investment May Look Like
2021 was a busy year in the medtech investment space. How will 2022 compare?
You may also be interested in...
Shortsellers Say Gingko BioWorks Is ‘Colossal Synthetic Biology Scam'
The company claims its synthetic biology technology will revolutionize manufacturing but its share have dipped after the fraud allegations.
Pandemic Perspectives: A Lasting Impact On Medtech, But Not Dealmaking
The COVID-19 pandemic has fundamentally changed health care and the life sciences, KPMG analyst Kristin Pothier concludes in a new report on the medtech investment outlook.
Hologic Continues Spending Spree With $230M Tuck-In Acquisition Of Biotheranostics
Hologic’s recent buy-outs put it in a strengthened growth and competitive position beyond COVID.